|
 As part of the agreement in principle, with details yet to be
hammered out, Stada will get exclusive marketing rights in Europe
for generic oncology drugs developed and produced by Hetero. Stada
will also get a sub-license in further regions outside India and the
United States.
The alliance covers cancer drugs that will lose patent protection
between 2016 and 2020 and Stada will decide at a later stage whether
Hetero compounds will also go its existing oncology drugs, Stada
Chief Executive Hartmut Retzlaff said at a press conference.
Financial terms were not provided.
(Reporting by Ludwig Burger; Editing by Georgina Prodhan)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
